Alumis Inc. · NASDAQ:ALMS
Alumis — Technical Presentation (May 2026)
21 slides from Alumis's technical presentation, May 14, 2026
Slide 1: Envudeucitinib (ESK-001) in Moderate-to-Severe Plaque Psoriasis: 24-Week Phase 3 Results
Envudeucitinib (ESK-001) in Moderate-to-Severe Plaque Psoriasis: 24-Week Results From the Randomized, Double-Blind, Active Comparator- and Placebo- Controlled, Phase 3 ONWARD1 and 2 Studies Andrew Blauvelt1, Howard Sofen2, April Armstrong3, Benjamin Ehst4-6, Jennifer Soung7, Maryam Shayesteh Alam8,
Slide 2: Disclosures
Disclosures 〉 Presenting author: AB has served as a speaker for and received honoraria from Almirall, Eli Lilly, LEO Pharma, Sanofi, and UCB; has served as a scientific adviser for and received honoraria from AbbVie, Almirall, Alumis Inc., Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeut
Slide 3: Envudeucitinib: A Next-Generation TYK2i for Moderate-to-Severe Psoriasis
Envudeucitinib: A Next-Generation TYK2i for Moderate-to-Severe Psoriasis 〉 Envudeucitinib, a next-generation, oral, allosteric TYK2i, provides maximal inhibition over a 24-hour period in patients with psoriasis1,2 〉 STRIDE Phase 2 and its open-label extension results demonstrated the favorable benef
Slide 4: ONWARD1 and ONWARD2: Study Designs and Endpoints
ONWARD1 and ONWARD2: Study Designs and Endpoints Coprimary Endpoints (vs Placebo) 〉 PASI 75 ONWARD1 and ONWARD2a 〉 sPGA-0/1 Key Secondary Endpoints (vs Placebo or Apremilast) 〉 PASI 75/90/100 Envudeucitinib 40 mg BID (n = 459; 433) Rollover to 2:1:1 Randomization 〉 sPGA-0/1 〉 Change from baseline in
Slide 5: Baseline Demographics and Disease Characteristics Were Balanced Across Arms
Baseline Demographics and Disease Characteristics Were Balanced Across Arms and Representative of a Typical Moderate-to-Severe Population ONWARD1 ONWARD2 Envudeucitinib Apremilast Envudeucitinib Apremilast 40 mg BID Placebo 30 mg BID 40 mg BID Placebo 30 mg BID n = 459 n = 230 n = 223 n = 433 n = 21
Slide 6: Robust and Statistically Significant PASI Response Rates at Week 16
Robust and Statistically Significant PASI Response Rates at Week 16 Almost 30% of patients receiving envudeucitinib achieved PASI 100 at Week 16 ONWARD1 ONWARD2 Envudeucitinib 40 mg BID (n = 459) Placebo (n = 230) Apremilast 30 mg BID (n = 223) Envudeucitinib 40 mg BID (n = 433) Placebo (n = 211) Ap
Slide 7: Sustained and Continued PASI Response Rates Through Week 24
Sustained and Continued PASI Response Rates Through Week 24 Approximately 65% and 40% of patients achieved PASI 90 and PASI 100 with envudeucitinib at Week 24 ONWARD1 ONWARD2 Envudeucitinib 40 mg BID (n = 459) Placebo (n = 230) Apremilast 30 mg BID (n = 223) Envudeucitinib 40 mg BID (n = 433) Placeb
Slide 8: Rapidly Increasing, Statistically Significant PASI 90 Response Rates
Envudeucitinib Resulted in Rapidly Increasing, Statistically Significant PASI 90 Response Rates vs Placebo and Apremilast Early onset of action: separation vs placebo observed at Week 4 ONWARD1 ONWARD2 Envudeucitinib 40 mg BID (n = 459) Placebo (n = 230) Apremilast 30 mg BID (n = 223) Envudeucitinib
Slide 9: Robust and Progressive Improvement in PASI 100 Response Rates Over Time
Envudeucitinib Demonstrated Robust and Progressive Improvement in PASI 100 Response Rates Over Time Approximately 40% complete skin clearance at Week 24 without evidence of plateau ONWARD1 ONWARD2 Envudeucitinib 40 mg BID (n = 459) Placebo (n = 230) Apremilast 30 mg BID (n = 223) Envudeucitinib 40 m
Slide 10: Significant sPGA-0/1 and sPGA-0 Responses
Envudeucitinib Demonstrated Significant sPGA-0/1 and sPGA-0 Responses Approximately 60% and 30% of patients receiving envudeucitinib achieved sPGA-0/1 and sPGA-0 at Week 16, and responses continued to improve through Week 24 ONWARD1 ONWARD2 Envudeucitinib 40 mg BID (n = 459) Placebo (n = 230) Apremi
Slide 11: Visible Skin Improvement by Week 2 With Envudeucitinib
Visible Skin Improvement by Week 2 With Envudeucitinib Week Week 0 2 Week Week 8 16 11 Patient with severe disease (PASI, 22.3; sPGA, 4) at baseline. PASI, Psoriasis Area and Severity Index; sPGA, static Physician’s Global Assessment. Envudeucitinib is investigational; not yet reviewed by regulatory
Slide 12: Envudeucitinib Resulted in Rapid and Significant Skin Improvement
Envudeucitinib Resulted in Rapid and Significant Skin Improvement Week Week 0 2 Week Week 8 16 12 Patient with moderate disease (PASI, 12.4; sPGA, 3) at baseline. PASI, Psoriasis Area and Severity Index; sPGA, static Physician’s Global Assessment. Envudeucitinib is investigational; not yet reviewed
Slide 13: Substantial Skin Improvement Achieved After Switching to Envudeucitinib in 8 Weeks
Substantial Skin Improvement Achieved After Switching to Envudeucitinib in 8 Weeks Placebo Envudeucitinib Week 0 Week 16 Week 24 Patient with severe disease at baseline (PASI, 31.8; sPGA, 4) who crossed over from placebo to envudeucitinib at Week 16. PASI, Psoriasis Area and Severity Index; sPGA,
Slide 14: Rapid, Significant, and Sustained Scalp Psoriasis Improvement With Envudeucitinib
Rapid, Significant, and Sustained Scalp Psoriasis Improvement With Envudeucitinib Approximately 3 in 4 patients receiving envudeucitinib achieved ss-PGA-0/1a at Week 24, with over 30% response as early as Week 4 ONWARD1 ONWARD2 Envudeucitinib 40 mg BID (n = 274) Placebo (n = 135) Apremilast 30 mg BI
Slide 15: Envudeucitinib Rapidly Reduced Itch With Deepening Response Over Time
Envudeucitinib Rapidly Reduced Itch With Deepening Response Over Time On average ˃4-point mean decrease from baseline in worst pruritus NRS by Week 12, with continued symptom improvement over time ONWARD1 ONWARD2 Week Week 0 4 8 12 16 20 24 0 4 8 12 16 20 24 Worst Pruritus NRS, Δ Baseline, LSM (95%
Slide 16: Envudeucitinib Treatment Significantly Improved Patient Quality of Life
Envudeucitinib Treatment Significantly Improved Patient Quality of Life Approximately 50% of patients receiving envudeucitinib reported DLQI-0/1a by Week 12, with continued improvement through Week 24 ONWARD1 ONWARD2 Envudeucitinib 40 mg BID (n = 424) Placebo (n = 211) Apremilast 30 mg BID (n = 207)
Slide 17: Benefits in Itch Reduction and Quality of Life Visible Before Skin Clearance
Benefits in Itch Reduction and Quality of Life Visible Before Skin Clearance Patients receiving envudeucitinib showed robust, early improvements in DLQI and itch that preceded PASI 90 responses ONWARD1 ONWARD2 Envudeucitinib 40 mg BID Envudeucitinib 40 mg BID 80 0 80 0 Itch Δ Baselinea (95% CI) Itch
Slide 18: ONWARD1 and ONWARD2 Pooled Safety Through Week 16
ONWARD1 and ONWARD2 Pooled Safety Through Week 16 Through Week 16 Envudeucitinib Apremilast 40 mg BID Placebo 30 mg BID n (%) n = 890 n = 441 n = 438 ≥1 TEAE 524 (58.9) 166 (37.6) 223 (50.9) ≥1 SAE 19 (2.1) 5 (1.1) 5 (1.1) TEAE leading to treatment 30 (3.4) 7 (1.6) 9 (2.1) discontinuation TEAE grade
Slide 19: ONWARD1 and ONWARD2 Pooled Safety Through Weeks 16 and 24
ONWARD1 and ONWARD2 Pooled Safety Through Weeks 16 and 24 Through Week 16 Through Week 24 Envudeucitinib Placebo to Overall Envudeucitinib Apremilast 40 mg BID Envudeucitinib Envudeucitinib Apremilast 40 mg BID Placebo 30 mg BID only 40 mg BID 40 mg BID 30 mg BID n (%) n = 890 n = 441 n = 438 n = 89
Slide 20: Conclusions: Envudeucitinib delivered early and progressively deepening skin clearance
Envudeucitinib, a next-generation TYK2i, delivered early and progressively deepening skin clearance, with meaningful improvements in patient-reported outcomes in ONWARD1 and 2 〉All primary and secondary efficacy endpoints met, with approximately 65% and 40% of patients receiving envudeucitinib achie
Slide 21: Acknowledgments
Acknowledgments 〉 The Authors thank the patients and their families for their participation and the study sites and teams for their facilitation of the ONWARD clinical studies 〉 The Authors thank Komal Bawa, PharmD, of Alumis Inc., for assistance with data publication and editorial review. Writing a